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Cell-surface expression of CD4 reduces HIV-1 infectivity by
blocking Env incorporation in a Nef- and Vpu-inhibitable manner
Juan Lama*†, Aram Mangasarian†‡ and Didier Trono‡
Background: Human immunodeficiency virus-1 (HIV-1) infection decreases
the cell-surface expression of its cellular receptor, CD4, through the combined
actions of Nef, Env and Vpu. Such functional convergence strongly suggests
that CD4 downregulation is critical for optimal viral replication, yet the
significance of this phenomenon has so far remained a puzzle. 
Results: We show that high levels of CD4 on the surface of HIV-infected cells
induce a dramatic reduction in the infectivity of released virions by the
sequestering of the viral envelope by CD4. CD4 is able to accumulate in viral
particles while at the same time blocking incorporation of Env into the virion.
Nef and Vpu, through their ability to downregulate CD4, counteract this effect.
Conclusions: The CD4-mediated ‘envelope interference’ described here
probably explains the plurality of mechanisms developed by HIV to
downregulate the cell-surface expression of its receptor. 
Background 
The recognition of the cell-surface glycoprotein CD4 by
the envelope of human immunodeficiency virus (HIV)
initiates a series of events that culminates in the fusion of
the viral and cellular membranes and in the delivery of the
inner components of the virion into the cytoplasm of
target cells [1–5]. Subsequently, CD4 expression on the
surface of HIV-1-infected cells is downregulated by the
combined actions of three viral proteins: Nef, envelope
(Env) and Vpu [2,4,6–10]. Of these, Nef acts the most
rapidly, both because it is an early viral gene product
[11,12] and because it triggers the accelerated internaliza-
tion of CD4 molecules that have already reached the cell
surface [13–15]. In contrast, Env and Vpu are produced
from a bicistronic late viral mRNA [16] and affect newly
synthesized CD4 molecules. Env forms a complex with
CD4 in the endoplasmic reticulum (ER) [17,18] and Vpu
triggers the degradation of receptor molecules thus
retained in this early compartment [10]. Although mecha-
nistically distinct, the effects of Nef, Env and Vpu are
additive, ensuring the almost complete elimination of
CD4 from the surface of cells productively infected with
HIV-1 [13,19].
Despite this good understanding of the mechanisms of
HIV-induced CD4 downregulation, the functional signifi-
cance of this event is not understood, although a few
hypotheses have been formulated. Eliminating the main
viral receptor from the surface of HIV-infected cells
might avoid multiple superinfection events that could
lead to premature cell death [20]. Alternatively, by
analogy with the action of influenza virus neuraminidase,
CD4 downregulation could prevent the trapping and
aggregation of outgoing virions on the surface of producer
cells [21–23]. Finally, CD4 regulation could alter T-cell
activation pathways to favor viral gene expression, for
instance by increasing the intracellular levels of free Lck
tyrosine kinase, as observed in other systems [24].
However, none of these models is yet supported by con-
crete experimental evidence. 
Difficulty in maintaining a productive HIV infection in
cell lines expressing high levels of CD4 has been reported
[25], but the viral countermeasures were not investigated
and the mechanism of the inhibition was not elucidated.
Here we reveal an important role for CD4 downregulation
in HIV infection, by showing that this phenomenon is
crucial for preserving the full infectivity of HIV-1 virions.
Results
Dose-dependent inhibition of HIV-1 infectivity by CD4
An effect of CD4 on HIV-1 infectivity was first assessed
using a luciferase-expressing HIV-based retroviral vector
system. Vector particles were produced by transfecting
either 293T or 293T-CD4 cells with a mixture of three
DNAs as described previously [26–28]: an HIV-derived
packaging plasmid, an Env expression construct, and the
retroviral vector DNA itself. Wild-type and nef-defective
versions of the packaging construct, as well as HIV-1 Env
derived from either the T-cell tropic (T-tropic) HXB2 or
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the macrophage-tropic (M-tropic) ADA isolates, were
compared. Infectivity was tested by measuring the
luciferase activity induced in HOS-CD4-CCR5 cells
exposed to the virions, and normalizing for the p24 capsid
antigen content of the inoculum (Figure 1a). These cells
express both the CXCR4 and the CCR5 HIV-1 co-recep-
tors, and are thus susceptible to both T- and M-tropic
HIV-1 strains [29]. CD4 expression had no effect on the
efficiency of particle release and did not affect the infec-
tivity of wild-type virions. It significantly further
decreased the infectivity of particles produced from the
nef-deleted packaging construct, however; from two- to
threefold for virus released by 293T cells to more than
20-fold for virions generated in 293T-CD4 cells. 
The fact that CD4 affected the infectivity of nef-defective
(∆Nef) but not wild-type virus suggested that the inhibi-
tion might be proportional to the cell-surface levels of
CD4. To test this, luciferase-expressing vector particles
coated with the T-tropic HXB2 Env were generated in
293T cells transfected with increasing amounts of a
CD4-expressing vector. The vector particles were then
used to infect HOS-CD4-CXCR4 cells, which overexpress
CXCR4. Infectivity was scored by measuring luciferase
activity in these targets, normalizing for the amount of p24
in the inoculum. In addition, CD4 levels on the surface of
producer cells were examined using flow cytometry
(Figure 1b). Whereas small amounts of CD4 (following
transfection of 0.3 µg CD4-expressing DNA) only slightly
reduced the infectivity of wild-type virions, higher levels
had a dramatic effect. For instance, wild-type vector parti-
cles produced in cells transfected with 3 µg CD4 DNA
were more than 10 times less infectious that those pro-
duced in CD4-negative cells. The greater sensitivity of
nef-defective viruses was confirmed in this experimental
setting: transfection of 1 µg CD4 plasmid caused a twofold
reduction in the infectivity of wild-type particles but a
10-fold reduction in that of nef-defective virions. In both
cases, a strict correlation was observed between the
surface levels of CD4 in virus-producing cells and the
degree of CD4-mediated inhibition. Experiments with
HIV-1 proviral DNA transfected in the presence of
increasing amounts of CD4 expression vector gave similar
results (data not shown). It should be noted that, in this
system, CD4 did not affect the efficiency of virion produc-
tion (data not shown). 
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Figure 1
CD4-mediated inhibition of HIV-1 infectivity.
(a) Luciferase-expressing HIV-1 vector
particles coated with either the T-tropic HXB2
(left) or the M-tropic ADA (right) envelope
were produced by transient transfection of
293T or 293T-CD4 cells with a wild-type
(WT) or a nef-defective packaging construct.
Relative infectivity was determined by
measuring luciferase production in HOS-
CD4-CCR5 target cells, normalizing for p24
antigen content of the inoculum. CD4
expression did not affect the efficiency of
particle release. Results, expressed as a
percentage of the infectivity of wild-type
particles produced from CD4-negative 293T
cells, represent the mean ± standard error
(SEM) determination from three experiments.
(b) Wild-type or nef-defective HXB2-Env-
coated vector particles were produced from
293T cells transfected with increasing
amounts of a CD4-expressing plasmid. The
amounts of luciferase activity induced in HOS-
CD4-CXCR4 target cells by the resulting virus
are shown in the left panel. The levels of CD4
in 293T cells, determined using flow
cytometry at the time of virus harvest, are
shown in the right panel. CD4 levels are given
in arbitrary units, calculated by multiplying the
percentage of CD4-positive cells by the
median of the fluorescence signal as
previously described [66]. 
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The inhibitory effect of CD4 requires an interaction with Env
A probable mechanism for the observed inhibition of
HIV-1 infectivity is that CD4 interferes with Env func-
tion. To test this hypothesis, retroviral vector particles
pseudotyped with the G protein of vesicular stomatitis
virus (VSV) were produced in 293T cells transfected with
increasing amounts of a CD4-expressing plasmid, and
their infectivity was analyzed using HOS-CD4-CCR5
cells as targets (Figure 2a). As described previously
[28,30], the absence of Nef did not impair the infectivity
of the VSV G-pseudotyped HIV-1 virions but instead
slightly stimulated it. Moreover, CD4 had no effect in this
setting, even when expressed at levels higher than those
required for almost complete inhibition of vector particles
coated with HIV-1 Env. The CD4-mediated inhibition
thus seems to require that viruses be coated with the
HIV-1 envelope.
CD4 binds to the gp120 surface moiety of Env through its
extracellular region [31], whereas the CD4 cytoplasmic
tail, which associates with the protein tyrosine kinase
p56lck (Lck), is the target of Nef and Vpu [13,32–38]. A
CD4 derivative (44X) lacking the cytoplasmic domain is
expressed at high levels on the cell surface and is insensi-
tive to Nef [13,39]. As one would predict, this CD4 variant
strongly inhibited the infectivity of both wild-type and
∆Nef vector particles (Figure 2b). Reciprocally, a
CD8/CD4 chimera (884) that contained the extracellular
and transmembrane domains of CD8 fused to the cyto-
plasmic tail of CD4 did not significantly reduce the infec-
tivity of HIV-based particles, even though this fusion
protein was expressed at high levels on the cell surface. As
expected, a truncated CD8 variant lacking a cytoplasmic
tail (88X) behaved in a similar way. The extracellular
domain of CD4 is therefore both necessary and sufficient
for interference with HIV-1 infectivity, at least if it is part
of an integral transmembrane protein. Furthermore, the
rescuing effect of Nef apparently depends on the conser-
vation of CD4 determinants that allow for downregulation
by this viral protein. In support of this model, a CD4
variant mutated in a dileucine motif critical for Nef
responsiveness [13] was equally active on wild-type and
∆Nef virions (data not shown). 
Nef and Vpu counteract the CD4-mediated inhibition of
HIV-1 infectivity
Our results indicate that the inhibition of HIV-1 infectivity
by CD4 is proportional to the level of CD4 at the cell
surface, possibly explaining how Nef prevents this inhibi-
tion. To confirm this and to evaluate whether Vpu, another
downregulator of CD4, has a similar positive influence on
624 Current Biology, Vol 9 No 12
Figure 2
CD4-mediated inhibition of HIV-1 infectivity requires CD4–Env binding.
(a) Relative infectivity of wild-type (WT) and nef-defective, luciferase-
expressing, vector particles pseudotyped with the G protein of VSV
and produced from 293T cells either mock-transfected (Mock) or
transfected with increasing amounts of a CD4-expressing plasmid,
using HOS-CD4-CCR5 cells as targets. Results are the means from
two experiments each performed in duplicate. Data are presented as
percentage of the infectivity of wild-type particles produced in the
absence of CD4. (b) The same experimental system was used to test
the inhibitory effect of co-transfection with 1 µg of expression vectors
expressing various CD4 and CD8 derivatives. The three-letter code
denotes the source of the various domains of these molecules (see
text). The top panel shows the relative infectivity of particles on HOS-
CD4-CXCR4 cells (with wild-type virions produced in the absence of
inhibitor serving as reference). None of the CD4 and CD8 derivatives
affected the efficiency of particle release (data not shown). The bottom
panel shows cell-surface expression of CD4/CD8 derivatives,
estimated using flow cytometry with antibodies specific for CD4 (that
is, CD4 and 44X) or CD8 (that is, 884 and 88X). Results are
representative of two independent experiments. 
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HIV-1 infectivity, we compared the CD4 sensitivities of
vector particles generated from several singly and multiply
deleted HIV-1 packaging constructs and coated with the
HXB2 envelope (Figure 3). In the absence of CD4 expres-
sion, all vector particles exhibited comparable transduction
efficiencies. In the presence of CD4, the efficiency of virion
release was unaffected, irrespective of the packaging con-
struct (data not shown). Furthermore, particles with defec-
tive virion infectivity factor (vif) or viral protein R (vpr)
genes were as infectious as wild-type particles. In contrast,
virions generated from packaging constructs additionally
mutated in nef, or in nef and vpu, were impaired to extents
proportional to the levels of CD4 on the surface of the pro-
ducer cells. CD4 levels were highest on cells transfected
with the quadruply defective packaging plasmid, and the
infectivity of the virions produced in this case was the
lowest. Nef and Vpu thus seem to exert additive influences
to counteract the CD4-mediated inhibition of HIV-1 infec-
tivity, most probably through their ability to induce CD4
downregulation. Because the transducing genome encoding
luciferase does not encode any proteins necessary for its
packaging, these experiments show that the accessory pro-
teins Nef and Vpu work in trans to complement infectivity. 
To confirm and extend the results obtained with the retro-
viral vectors, we tested the CD4 sensitivity of the follow-
ing HIV-1 mutants: ∆Nef, ∆Vpu, ∆Nef/∆Vpu, and
NefWL58AA. This last mutation is of interest because it
targets the CD4-binding pocket of Nef, almost completely
inhibiting CD4 downregulation, while leaving much of
the Nef-mediated infectivity enhancement intact if virion
production occurs in a CD4-negative setting [40]. Trans-
fected proviral DNAs were all derived from the previously
described R9 clone, which expresses all HIV-1 accessory
genes. When produced in the absence of CD4, both the
nef-deleted virus and the double mutant deleted in nef and
vpu were found to be approximately 15% as infectious as
wild type, whereas the vpu-deleted and the NefWL58AA
viruses retained roughly 60 and 40% of initial infectivity
respectively (Figure 4a, top). 
As in the vector system, the ability to resist the presence of
CD4 in the producer cells correlated with the ability to
downregulate CD4 in the viral producer cells (Figure 4a,
bottom and Figure 4b). The mutant that experienced the
most severe decline in infectivity relative to initial levels
was the ∆Nef/∆Vpu double mutant (96%), followed by
∆Nef (93%), NefWL58AA (89%), and finally ∆Vpu (77%)
(Figure 4a, bottom). In contrast, the wild-type virus lost
only 27% of its original infectivity when CD4 was present
in the viral producer cells. The fact that the NefWL58AA and
∆Nef HIV-1 derivatives responded to the introduction of
CD4 with relatively similar large losses in infectivity sug-
gests that CD4 downregulation is a significant component
of the ability of Nef to enhance infectivity. The NefWL58AA
mutant retained its higher absolute level of infectivity 
relative to ∆Nef, confirming that two distinct effects con-
tribute to Nef-mediated enhancement of HIV-1 infectiv-
ity: the downregulation of CD4, and the previously
described stimulation of proviral DNA synthesis [41–43]. 
High cell-surface CD4 expression alters the Env content of
HIV-1 virions
One possible explanation for the above observations is
that CD4 sequesters the HIV-1 envelope. To test this
possibility, we examined the protein content of virions
produced in the presence and absence of CD4. This
analysis revealed that CD4-mediated inhibition of viral
infectivity probably has two components. First, there is an
almost complete, CD4-dependent block to the proper
incorporation of Env in viruses harboring deletions in nef
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Figure 3
Nef and Vpu counteract the inhibitory effect of CD4. (a) Relative
infectivity of retroviral particles coated with the HXB2 envelope and
produced from packaging constructs either wild-type or mutated in
various HIV-1 genes, in the presence or absence of CD4. For each
type of vector, transducing ability in the absence of CD4 constituted
the 100% reference value. Results are from two experiments each
performed in duplicate ± SEM. (b) Cell-surface levels of CD4 in the
293T producer cells from a representative experiment, determined by
flow cytometry. See text for description of mutants. 
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or vpu; second, high levels of CD4 are present in the nef-
and vpu-defective virions (Figure 5a). 
The Env content of the virions was measured by western
blotting with antibodies against both the gp41 transmem-
brane moiety and the gp120 surface moiety of the enve-
lope as we were concerned that the presence of CD4 on
the particles might cause trapping of gp120 molecules shed
from the cell surface. When released from CD4-expressing
cells, viruses mutated in nef and/or vpu contained almost no
gp41, and instead carried large amounts of CD4. In the
absence of Vpu, however, the particles still had some
gp120, whether nef was functional or not. Examination of
cell-surface expression of Env in cells producing the
various viruses solved this puzzle (Figure 5b). Env was
almost 20 times more abundant on the surface of cells
transfected with the ∆Vpu proviral construct. 
We attribute this effect to the fact that the vpu mutation
used in these experiments is an inactivation of the vpu
start codon. Because Vpu and Env are translated from the
same bicistronic mRNA, the removal of the vpu initiator,
located upstream, greatly facilitates Env synthesis.
Higher levels of gp120 are shed into the supernatant and
subsequently bind CD4 molecules carried by the virions.
The increase in Env synthesis is reflected not only in its
cell-surface expression, but also in the slightly increased
levels of gp41 found in purified virions, for example
when comparing the ∆Nef and ∆Nef/∆Vpu viruses in the
presence of CD4. The high levels of Env on the surface
of ∆Vpu-producing cells contributed little to HIV infec-
tivity, however, emphasizing the efficacy of the
CD4-mediated block to Env incorporation into the
virion. Interestingly, the cell-surface expression of Env
was also increased in cells releasing ∆Nef HIV-1, com-
pared with wild-type infected cells. This effect was much
less pronounced than in ∆Vpu-producing cells, however.
As expected, we found that the CD4-mediated block to
Env incorporation correlated with a decreased efficiency
of viral entry into target cells, as measured by p24 uptake
(data not shown).
Together with the functional analyses, these data indicate
that CD4 inhibits HIV-1 infectivity by blocking the effi-
cient incorporation of the viral envelope into the virion;
the envelope, therefore, cannot act to mediate viral entry
into cells. Our study also demonstrates that Nef and Vpu
have evolved to counteract this inhibitory effect by down-
regulating the cell-surface expression of CD4.
Discussion
Cells infected with a retrovirus become resistant to rein-
fection by a virus bearing the same envelope glycoprotein
[44,45]. This phenomenon is known as receptor interfer-
ence, and for simple retroviruses such as the Rous sarcoma
virus (RSV) or the murine leukemia virus (MLV) it
reflects solely the action of Env [46]. Receptor downregu-
lation is more complex in the case of HIV; Nef and Vpu
626 Current Biology, Vol 9 No 12
Figure 4
HIV-1 nef and vpu mutant viruses are more
sensitive to CD4 expression in producer cells.
(a) Relative infectivity of HIV-1 viral particles
produced by transient transfection of 293T
cells (top). Cells were transfected with 20 µg
proviral DNA for viral production.
Supernatants were filtered through 0.45 µm
filters and normalized for reverse transcriptase
(RT) activity before addition to target P4-2
cells, which harbor the HIV-LTR-driven
β-galactosidase gene. The bottom panel
shows the percentage of initial infectivity
retained when proviral DNA was co-
transfected with 1 µg CD4 expression vector.
Results for each condition are from at least
three separate transfection/infection series.
(b) Cell-surface levels of CD4 on viral
producer cells in a representative experiment
following co-transfection of 1 µg CD4
expression vector with proviral DNA. See text
for descriptions of mutants. 
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add their influence to that of the viral envelope to elimi-
nate CD4 almost completely from the surface of produc-
tively infected cells. This functional redundancy was
unexplained, even taking into account the higher cell-
surface levels of CD4 compared with those of other
known retrovirus receptors [47]. The work reported here
suggests a solution to this puzzle, by showing that the
combined actions of Nef and Vpu can prevent the CD4-
mediated inhibition of virion infectivity that is observed
when high levels of CD4 are present on the surface of
HIV-1-infected cells. Inhibition by CD4 reflects a seques-
tration of the viral envelope by this cellular receptor,
which results in a block of Env particle incorporation. We
propose calling this effect ‘envelope interference’, by
analogy with receptor interference, which it mirrors in
some aspects (Figure 6). 
The results reported here were in part obtained in trans-
fected epithelial cells because this system best allowed
examination of the relative effects of Nef, Vpu and CD4
in single and synchronous rounds of viral production. It
has been noted previously, however, that the ability of a
human T-lymphoid cell line to support and maintain a
productive infection was inversely proportional to its
surface levels of CD4 [25]. Furthermore, we had
reported that the defective phenotype of a virus express-
ing a Nef variant unable to downregulate CD4
(NefWL58AA) was more pronounced, compared with wild
type, when it was released from CD4-positive CEM
T-lymphoid cells than when it was produced by
CD4-negative 293 cells [40]. The present study provides
the functional and biochemical data that explain these
two observations. 
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CD4 alters the protein content of HIV-1 virions. (a) Lanes 1–8 show
western blots of virions purified by ultracentrifugation of supernatant
from cultures of 293T cells two days after transfection with the various
proviral constructs derived from the R9 wild-type clone (see text),
which contains all HIV-1 accessory genes. Loading of samples was
normalized according to reverse transcriptase activity. As a control, the
supernatant of cells transfected with the CD4 expression vector only
were processed in parallel (lane 9). As this sample contained no
reverse transcriptase activity, we loaded a volume corresponding to
the maximum volume loaded in the series of viral samples. A + sign in
the rows above the western blots indicates, from top to bottom, that:
proviral DNA was transfected into the viral producer cells (Virus); the
proviral genome contained nef; the proviral genome contained vpu;
and 1 µg of CD4 expression vector was cotransfected. The numbers at
the left indicate molecular mass markers in kDa. (b) Infected
CEM–GFP cells were analyzed by FACS for cell-surface expression of
gp41, the transmembrane moiety of Env, using the T32 monoclonal
antibody. Infected cells were gated by taking advantage of the
HIV-LTR driven green fluorescent protein (GFP) cDNA present in
these cells.
The HIV-1 envelope glycoprotein is synthesized as a
160 kDa precursor in the ER, where it undergoes several
modifications including disulfide bonding, folding,
N-linked glycosylation and oligomerization [48,49]. One
demonstrated role of Vpu is to induce the degradation of
CD4 molecules complexed with Env in the ER, and
thereby to liberate the viral envelope [10]. Once trans-
ported to the Golgi apparatus, Env is cleaved into its gp120
surface and gp41 transmembrane moieties, and is further
modified by alteration of its sugar residues before migrat-
ing to the cell surface. Steady-state levels of Env are then
downregulated in at least two ways. First, a significant frac-
tion of gp120 molecules is shed into the extracellular
milieu [49]. Second, the glycoprotein also undergoes inter-
nalization owing to the presence of a tyrosine-based endo-
cytosis signal in the cytoplasmic domain of gp41 [50,51].
Interestingly we found that levels of Env increased on the
surface of viral producer cells in the absence of Nef. This
effect was independent of the presence of CD4, as we
noted a similar phenomenon in T lymphocytes and CD4–
epithelial cells (data not shown). A negative effect of Nef
on the cell-surface expression of the HIV-1 envelope has
been reported previously [52]. In this study, it was also
indicated that Nef does not affect the biosynthesis and
maturation of the viral glycoprotein, nor the shedding of its
gp120 moiety into the extracellular space. Our data are at
odds with the previous claim that Nef-induced downregu-
lation of cell-surface Env can be abrogated by mutations
suppressing the CD4-binding ability of Env [52], as we
observe this effect in a CD4-negative setting. The origin of
this discrepancy is unclear, although in that other study a
vaccinia-based expression system was used, virions were
not examined, and CD4-negative producer cells were not
tested. The results presented here suggest that the Nef-
mediated downregulation of Env does not simply result
from the internalization of CD4–Env complexes, and raise
the possibility that Nef might influence the intracellular
trafficking of Env itself, a point worth further investigation. 
The HIV-1 envelope is normally recruited into virions
through specific interactions between the cytoplasmic tail
of gp41 and residues in the viral matrix protein (MA)
[53–55]. It is noteworthy that CD4 can block this process
without affecting the efficiency of viral budding. This sug-
gests that Env has a much higher affinity for CD4 than for
MA, or that MA cannot recognize Env within the context
of CD4–Env complexes. This latter defect could result
either from masking of critical Env determinants or from a
redistribution of the viral glycoprotein away from the gag
gene products when it is associated with CD4. One possi-
bility is that Env is perhaps redirected to a ‘non-budding’
region of the plasma membrane by CD4. Lck, which asso-
ciates with the cytoplasmic tail of CD4, is known to reside
in structures known as rafts or detergent-insoluble glyco-
lipid-enriched membrane microdomains (DIGs) [56].
Rafts are detergent-resistant regions of the membrane
where the activation machinery of T cells is concentrated
[57,58]. It would be interesting to determine whether CD4
also accumulates in rafts, even in the absence of Lck, and
whether it can drag Env into these structures. It might also
be instructive to ask whether the virus buds from regions
of the plasma membrane that do or do not correspond to
rafts. The efficient recruitment of CD4 into virions
strongly suggests that the receptor might inhibit HIV-1
infectivity not only by decreasing the efficiency of Env
incorporation into the virus particle, but also by saturating
628 Current Biology, Vol 9 No 12
Figure 6
Model of CD4-mediated inhibition of HIV-1
infectivity. In the wild-type virus infection (left
panel), both Nef and Vpu assist in
downregulating CD4, resulting in its near-
complete elimination from the surface of the
infected cell. Levels of Env on the cell surface
are not very high, but incorporation into the
virion is efficient. In the case of ∆Nef virus
(middle panel), CD4 levels are markedly
increased on the surface of the virus producer
cell. This has two effects: first, Env is
sequestered on the cell surface, possibly in a
non-budding region of the cell membrane, and
is therefore not efficiently incorporated into
the virion; second, the viral particle harbors
CD4 on its surface. With a virus lacking both
Nef and Vpu (right panel), the situation is
similar except that, because of the absence of
Vpu, CD4 levels are even higher on the cell
surface, and because of the deletion of the
vpu ATG in the bicistronic vpu/env mRNA,
there is much more Env on the plasma
membrane. This results in increased quantities
of gp120 being shed in the extracellular
space, with some of it binding to CD4 on the
virus surface. Despite the greater quantity of
Env protein on the cell when vpu is mutated,
CD4 is able to block incorporation of almost
all of this protein into the virus particle. 
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the CD4-binding sites of virus-associated envelope mole-
cules (Figure 6).
Nef can stimulate the infectivity of HIV-1 virions indepen-
dently of its ability to downregulate CD4 [41,42,59,60].
This positive effect of Nef is exerted at a post-uptake level
but is inapparent when virions enter cells by receptor-
mediated endocytosis, and correlates with a stimulation of
proviral DNA synthesis which probably reflects a stabiliza-
tion of the viral reverse transcription complex [30,41–43].
Here we show that Nef-induced CD4 downregulation also
participates in promoting HIV-1 infectivity, as nef-defec-
tive mutant viruses, as well as an HIV-1 derivative express-
ing a CD4 downregulation mutant of nef, are significantly
more sensitive to CD4 than their wild-type counterparts. 
Conclusions
We reveal here that high levels of CD4 on the surface of
an HIV-producing cell can block viral infectivity by inter-
fering with incorporation of the envelope into the virion.
Nef and Vpu, two accessory gene products of HIV-1 that
downregulate CD4, counteract this inhibition. This sug-
gests that blocking of Nef- and Vpu-mediated CD4 down-
regulation could have a profound impact on the spread of
HIV-1 in vivo. The remarkable progress made in under-
standing the molecular mechanisms of action of these two
viral proteins could be exploited by developing antiviral
strategies that target their function.
Materials and methods 
Plasmids
Expression of CD4 and CD4/CD8 chimeras was achieved with the
cytomegalovirus (CMV)-based mammalian expression vector pCMX
[61]. Plasmids used to generate HIV-1-derived vector particles carrying
a luciferase reporter transgene have been described [26–28]. These
particles were either pseudotyped with the G protein of VSV (VSV-G)
or coated with the HIV-1 envelope glycoprotein. The T-tropic HXB2-
derived HIV-1 envelope was produced from plasmid ∆GPVV-R7-dhfr, a
variant of the previously described R7-dhfr construct [62] in which the
sequences encoding Gag, Pol, Vpr, Vif and Nef have been inactivated.
The M-tropic ADA-derived HIV-1 envelope expression vector was
obtained from D. Littman [29]. HIV-1 virions were made using the previ-
ously described R9 construct, in which all HIV-1 accessory genes are
present [40]. All mutations were made in this context. ∆NefR9 and
NefWL58AAR9 have been described previously [40]. The vpu deletion
mutants were constructed by a PCR mutagenesis strategy which
results in the substitution of the first two codons of vpu: 5′-ATGCCA-3′
with 5′-ACTAGT-3′, destroying the initiation codon and introducing a
SpeI site for verifying the presence of the mutation. 
Cells
293T cells, a derivative of the human kidney fibroblastic 293 cell line
that stably expresses the simian virus 40 large T antigen (a gift from G.
Nolan), were used for production of HIV-1 particles. Some of the exper-
iments were carried out with a 293T subclone, 293T-CD4, that stably
expresses human CD4. HIV-1 infectivity assays were carried out in
CD4+ HeLa-derived P4 cells, which contain the β-galactosidase gene
under the control of the HIV promoter, allowing the easy scoring of
infected cells by X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyra-
noside) staining [63]. Transduction efficiency of HIV-derived luciferase
vectors was tested in HOS-CD4-CXCR4 or HOS-CD4-CCR5, which
are human osteosarcoma cells modified to express CD4 and either the
T-tropic CXCR4 or the M-tropic CCR5 co-receptors [29]. HOS-CD4-
CCR5 expresses low levels of CXCR4 and can be infected by either T-
or M-tropic HIV-1 isolates. Both cell lines were a gift from N. Landau,
obtained through the National Institutes of Health AIDS Research and
Reference Reagent Program. CEM-GFP cells (a gift from A. Gervaix)
are a T-lymphocytic cell line with a stably integrated green fluorescent
protein (GFP) expression cassette driven by the HIV-1 long terminal
repeat (LTR) [64]. As a result, these cells inducibly express GFP in
response to the presence of Tat, the HIV-1 transcriptional transactiva-
tor. GFP-positive cells are thus considered infected, and can be gated
separately by fluorescence-activated cell sorter (FACS) analysis. All
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM),
except for CEM-GFP cells, which were grown in RPMI, and supple-
mented with 10% fetal calf serum (FCS) with addition of 1 µg/ml
puromycin (Sigma) for the HOS-derived lines. 
Transfections, virus preparations and infections. 
293T cells were transfected by the calcium phosphate method [39].
HIV-based particles pseudotyped with either HIV-1 gp120 or VSV-G
proteins were harvested after 48 h and filtered through 0.45 µm nitro-
cellulose membranes. Samples containing vector particles were ana-
lyzed for p24 antigen content by an enzyme-linked immunoabsorbent
assay (DuPont). Samples containing HIV were normalized by the
reverse transcription (RT) assay (described below).
To examine virion-associated proteins, particles were pelleted at
26,000 rpm in an SW28 rotor (Beckman) for 1.5 h at 4°C. The liquid
was aspirated, and the walls of the tube wiped before resuspending
the pellet in 150 µl phosphate-buffered saline (PBS) for 10 min at room
temperature. Samples were stored at 4°C until RT determination was
performed (approximately 5 h later). Samples were then diluted with
PBS to give equal concentrations of RT activity, and then denatured by
the addition of 1/6 volume of 6× sample buffer (500 mM Tris–HCl,
12% SDS, 60% glycerol, 0.01% bromophenol blue, 20% β-mercapto-
ethanol), followed by heating at 96°C for 5 min.
To determine the infectivity of HIV-1 particles, 5 × 104 P4 cells per well
(seeded in 24-well trays) were infected in 1 ml of DMEM supplemented
with 10% FCS for 24 h with amounts of virions corresponding to 1/1,
1/5, 1/25, and 1/125 dilutions of the least concentrated supernatant
after normalization for RT activity. The medium was changed 24 h after
infection, and cells were incubated for an additional 24 h at 37°C. Cells
were then fixed and stained with X-gal. The numbers of blue foci were
counted under the light microscope. 
For preparation of HIV-based retroviral particles coated with either
VSV-G or gp120, a previously described procedure was followed
[26–28] with some modifications. 293T cells (1.5 × 106) were seeded
the day before transfection. Transfection was carried out with a mixture
of four plasmids: either 2.5 µg pMDG (encoding VSV-G) or 3.5 µg
HIV-1 env expression vector, 7.5 µg packaging construct (encoding
various HIV-1 proteins but not Env), 10 µg of the transfer vector pHR′-
CMVluc (expressing luciferase under the control of the immediate early
CMV promoter) and various amounts of a pCMX-based CD4 expres-
sion vector. After 2 days, supernatants were filtered through 0.4 µm
nitrocellulose membranes. To determine the infectivity of these parti-
cles, 1 × 105 HOS-derived cells (seeded in six-well trays 24 h before
infection) were exposed to 50 µl supernatant (containing approximately
25 ng p24) in 2 ml DMEM supplemented with 10% FCS and 8 µg/ml
polybrene. Twelve hours after infection the medium was replaced.
Two days later the cells were washed twice with TBS buffer (50 mM
Tris-HCl pH 7.8, 130 mM NaCl, 10 mM KCl, 5 mM MgCl2) and lysed in
200 µl of the same buffer supplemented with 0.5% Nonidet P-40
(NP-40). After clarification by centrifugation (14,000 rpm for 5 min in a
microfuge), lysates were assayed for luciferase activity.
The reverse transcriptase cocktail consisted of: 60 mM Tris-Cl pH 7.8,
75 mM KCl, 5 mM MgCl2, 0.1% NP-40, 1 mM EDTA, and 0.16 µg/ml
poly(A):oligo(dT). Just before use, 4 µl 1 M DTT, 20–40 µl [3H]TTP
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(1 mCi/ml) were added to each ml of cocktail. A sample of 20 µl of
1:10 dilution of detergent-inactivated virus (0.5% Triton X-100) was
added to 40 µl of the cocktail, and incubated for 2 h at 37°C. For each
determination, duplicate dilutions and RT reactions were performed.
The entire reaction was spotted on 2.3 cm Whatman DE81 circles that
were washed three times for 5 min in 2× SSC, and once in 95%
ethanol, before scintillation counting.
Protein analyses and antibodies
The cellular and viral levels of specific proteins were examined by
western blotting with the following antibodies: for HIV-1 gp120 a
mixture of three mouse monoclonal antibodies from the MRC AIDS
repository was used: 301 (at 1:500),.323 (at 1:1250) and 332 (at
1:1250). For HIV-1 gp41 western and FACS analysis the supernatant
of the T32 hybridoma cell line, a gift from Patricia Earl, was used [65].
T32 cells were grown in HyQ-CCM1 (Hyclone B5500-L) with
50 units/ml human IL-6. A monoclonal antibody from the NIH AIDS
repository was used to probe p24 capsid proteins; for CD4, rabbit anti-
serum obtained from the NIH AIDS Research and Reference Reagent
Program (AR 806) was used. Antibody binding was detected by
enhanced chemiluminiscence (ECL Western Blotting Kit, Amersham)
using horseradish peroxidase-conjugated immunoglobulin (Ig; Amer-
sham) according to the manufacturer’s instructions. 
Flow cytometry
293T cells were removed from dishes 2 days after transfection by
washing with calcium- and magnesium-free PBS. Cells were incubated
at 4°C for 45 min with saturating amounts of fluorescein- or R-phyco-
erythrin (RE)-conjugated antibodies specific for CD4 or CD8 (Dako),
washed twice with PBS, resuspended in 1% paraformaldehyde and
analyzed by flow cytometry on a Becton Dickinson FACSCalibur. Cell-
surface levels of the markers were expressed by multiplying the mean
fluorescence of positive cells by the percentage of positive cells as pre-
viously described [66]. Analysis of gp41 on infected CEM-GFP cells
was performed by incubating cells in a 1:10 dilution of T32 hybridoma
supernatant, washing twice with RPMI plus 1% FCS, and then incubat-
ing cells with a 1:30 dilution of a PE-conjugated anti-mouse Ig (Dako),
before fixation in 3% formaldehyde in PBS. Intact cells were selected
by gating the population in the forward and side scatter. 
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